Dynamics of virus-host interplay in HIV-1 replication

Current HIV Research

Volumn 4, Issue 2, 2006, Pages 117-130

  Sorin, Masha ^a   Kalpana, Ganjam V ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cellular proteins; HIV 1; Host restriction factors; Innate immunity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CYCLOPHILIN A; MESSENGER RNA; SMALL INTERFERING RNA; TRIPARTITE INTERACTION MOTIF 5ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CELL TRANSPORT; CELLULAR IMMUNITY; ENVIRONMENTAL FACTOR; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; INNATE IMMUNITY; LIFE CYCLE; NONHUMAN; RETROVIRUS; REVERSE TRANSCRIPTION; REVIEW; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; VIRUS REPLICATION;

EID: 33646193491     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206776055048     Document Type: Review

References (172)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM and Berger EA. (1996). CC CKR5: a RANTES, MIP-1 alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science. 272:1955-1958.
2. Anthony NJ. (2004). HIV-1 integrase: a target for new AIDS chemotherapeutics. Current Topics in Medicinal Chemistry. 4:979-990.
3. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W and Montagnier L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 220:868-871.
4. Belmonte L, Bare P, de Bracco MM and Ruibal-Ares BH. (2003). Reservoirs of HIV replication after successful combined antiretroviral treatment. Current Topics in Medicinal Chemistry. 10:303-312.
5. Berger EA, Murphy PM and Farber JM. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual Review of Immunology. 17:657-700.
6. Besnier C, Takeuchi Y and Towers G. (2002). Restriction of lentivirus in monkeys. Proceedings of the National Academy of Sciences USA. 99:11920-11925.
7. Best S, Le Tissier P, Towers G and Stoye JP. (1996). Positional cloning of the mouse retrovirus restriction gene Fv1. Nature. 382:826-829.
8. Bieniasz PD. (2003). Restriction factors: a defense against retroviral infection. Trends in Microbiology. 11:286-291.
9. Bock M and Stoye JP. (2000). Endogenous retroviruses and the human germline. Current Opinions in Genetics and Development. 10:651-655.
10. Boone LR, Innes CL and Heitman CK. (1990). Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. Journal of Virology. 64:3376-3381.
11. Bouyac-Bertoia M, Dvorin JD, Fouchier RA, Jenkins Y, Meyer BE, Wu LI, Emerman M and Malim MH. (2001). HIV-1 infection requires a functional integrase NLS. Molecular Cell. 7:1025-1035.
12. Bowerman B, Brown PO, Bishop JM and Varmus HE. (1989). A nucleoprotein complex mediates the integration of retroviral DNA. Genes and Development. 3:469-478.
13. Braaten D, and Luban J. (2001). Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. European Molecular Biology Organization Journal. 20:1300-1309.
14. Braaten D, Franke EK and Luban J. (1996). Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. Journal of Virology. 70:3551-3560.
15. Brown PO, Bowerman B, Varmus HE and Bishop JM. (1987). Correct integration of retroviral DNA in vitro. Cell. 49:347-356.
16. Brown PO, Bowerman B, Varmus HE and Bishop JM. (1989). Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proceedings of the National Academy of Sciences USA. 86:2525-2529.
17. Bukrinsky MI and Haffar OK. (1999). HIV-1 nuclear import: in search of a leader. Frontiers in Biosciences. 4:D772-781.
18. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S and Stevenson M. (1992). Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proceedings of the National Academy of Sciences USA. 89:6580-6584.
19. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M and Stevenson M. (1993). A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 365:666-669.
20. Bustin M and Reeves R. (1996). High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Progress in Nucleic Acid Research and Molecular Biology. 54:35-100.
21. Capiluppi B, Ciuffreda D, Quinzan GP, Sciandra M, Marroni M, Morandini B, Costigliola P, Guerra L, Di Pietro M, Fibbia GF, Visona R, Cusini M, Bressi C, Tambussi G and Lazzarin A. (2000). Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters. Journal of Biological Regulation and Homeostatic Agents. 14:58-62.
22. Carlson M and Laurent BC. (1994). The SNF/SWI family of global transcriptional activators. Current Opinions in Cell Biology. 6:396-402.
23. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, De Clercq E and Debyser Z. (2003). HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. Journal of Biological Chemistry. 278:372-381.
24. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C and Sodroski J. (1996). The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1135-1148.
25. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U and Margolis DM. (2000). The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. Journal of Virology. 74:6790-6799.
26. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG and Bieniasz PD. (2002). Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proceedings of the National Academy of Sciences USA. 99:11914-11919.
27. Cron RQ, Bartz SR, Clausell A, Bort SJ, Klebanoff SJ and Lewis DB. (2000). NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells. Clinical Immunology. 94:179-191.
28. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF and Weiss RA. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312:763-767.
29. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goodert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R and O'Brien SJ. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 273:1856-1862.
30. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR and Landau NR. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:661-666.
31. DesGroseillers L and Jolicoeur P. (1983). Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. Journal of Virology. 48:685-696.
32. Dorfman T, Bukovsky A, Ohagen A, Hoglund S and Gottlinger HG. (1994). Functional domains of the capsid protein of human immunodeficiency virus type 1. Journal of Virology. 68:8180-8187.
33. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP and Paxton WA. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:667-673.
34. Duan L, Ozaki I, Oakes JW, Taylor JP, Khalili K and Pomerantz RJ. (1994). The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. Journal of Virology. 68:4302-4313.
35. Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M and Malim MH. (2002). Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. Journal of Virology. 76:12087-12096.
36. Eichinger DJ and Boeke JD. (1988). The DNA intermediate in yeast Tyl element transposition copurifies with virus-like particles: cell-free Ty1 transposition. Cell. 54:955-966.
37. Engelman A. (2003). The roles of cellular factors in retroviral integration. Current Topics in Microbiology and Immunology. 281:209-238.
38. Farnet CM and Haseltine WA. (1991). Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. Journal of Virology. 65:1910-1915.
39. Farnet CM and Bushman FD. (1997). HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell. 88:483-492.
40. Fassati A and Goff SP. (2001). Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. Journal of Virology. 75:3626-3635.
41. Fauci AS. (1999). The AIDS epidemic--considerations for the 21st century. New England Journal of Medicine. 341:1046-1050.
42. Fauci AS. (2003). HIV and AIDS: 20 years of science. Nature Medicine. 9:839-843.
43. Feng Y, Broder CC, Kennedy PE and Berger EA. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:872-877.
44. Fouchier RA and Malim MH. (1999). Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Advances in Virus Research. 52:275-299.
45. Fouchier RA, Meyer BE, Simon JH, Fischer U and Malim MH. (1997). HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. European Molecular Biology Organization Journal. 16:4531-4539.
46. Franke EK and Luban J. (1995). Cyclophilin and gag in HIV-1 replication and pathogenesis. Advances in Experimental Medicine and Biology. 374:217-228.
47. Franke EK, Yuan HE and Luban J. (1994). Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 372:359-362.
48. Freed EO. (2001). HIV-1 replication. Somatic Cell Molecular Genetics. 26:13-33.
49. Freed EO. (2004). HIV-1 and the host cell: an intimate association. Trends in Microbiology. 12:170-177.
50. Furia B, Deng L, Wu K, Baylor S, Kehn K, Li H, Donnelly R, Coleman T and Kashanchi F. (2002). Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. J Biol Chem. 277:4973-4980.
51. Gallay P, Hope T, Chin D and Trono D. (1997). HIV-1 infection of nondividing cells through the recognition of integrase by the importin/ karyopherin pathway. Proceedings of the National Academy of Sciences USA. 94:9825-9830.
52. Gallay P, Stitt V, Mundy C, Oettinger M and Trono D. (1996). Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. Journal of Virology. 70:1027-1032.
53. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B and et al. (1984). Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 224:500-503.
54. Garber ME, Wei P and Jones KA. (1998). HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Cold Spring Harbor Symposium of Quantitative Biology. 63:371-380.
55. Gardner MB, Rasheed S, Pal BK, Estes JD and O'Brien SJ. (1980). Akvr-1, a dominant murine leukemia virus restriction gene, is polymorphic in leukemia-prone wild mice. Proceedings of the National Academy of Sciences USA. 77:531-535.
56. Garfinkel DJ, Boeke JD and Fink GR. (1985). Ty element transposition: reverse transcriptase and virus-like particles. Cell. 42:507-517.
57. Garrus JE, von Schwedler UK, Pomillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG and Sundquist WI. (2001). Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 107:55-65.
58. Gatignol A and Jeang KT. (2000). Tat as a transcriptional activator and a potential therapeutic target for HIV-1. Advances in Pharmacology. 48:209-227.
59. Gatignol A, Duarte M, Daviet L, Chang YN and Jeang KT. (1996). Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expression. 5:217-228.
60. Gaynor RB. (1995). Regulation of HIV-1 gene expression by the transactivator protein Tat. Current Topics in Microbiology and Immunology. 193:51-77.
61. Geijtenbeek TB and van Kooyk Y. (2003). DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Current Topics in Microbiology and Immunology. 276:31-54.
62. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG and van Kooyk Y. (2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 100:587-597.
63. Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, Thines D and De Wilde M. (1989). Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 59:103-112.
64. Goff A, Ehrlich LS, Cohen SN and Carter CA. (2003). Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release. Journal of Virology. 77:9173-9182.
65. Goff SP. (1996). Operating under a Gag order: a block against incoming virus by the Fv1 gene. Cell. 86:691-693.
66. Goff SP. (2001). Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. Journal of General Medicine. 3:517-528.
67. Goff SP. (2004). Retroviral restriction factors. Molecular Cell. 16:849-859.
68. Goila-Gaur R, Demirov DG, Orenstein JM, Ono A and Freed EO. (2003). Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. Journal of Virology. 77:6507-6519.
69. Gottlinger HG. (2001). The HIV-1 assembly machine. Aids. 15 Suppl 5:S13-20.
70. Greene WC and Peterlin BM. (2002). Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nature Medicine. 8:673-680.
71. Harris D and Engelman A. (2000). Both the structure and DNA binding function of the barrier-to-autointegration factor contribute to reconstitution of HIV type 1 integration in vitro. Journal of Biological Chemistry. 275:39671-39677.
72. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS and Malim MH. (2003). DNA deamination mediates innate immunity to retroviral infection. Cell. 113:803-809.
73. Hartley JW, Rowe WP and Huebner RJ. (1970). Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. Journal of Virology. 5:221-225.
74. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD and Towers GJ. (2003). Restriction of multiple divergent retroviruses by Lv1 and Refl. European Molecular Biology Organization Journal. 22:385-394.
75. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S and Bieniasz PD. (2004). Retrovirus resistance factors Refl and Lv1 are species-specific variants of TRIM5alpha. Proceedings of the National Academy of Sciences USA. 101:10774-10779.
76. Hindmarsh P, Ridky T, Reeves R, Andrake M, Skalka AM and Leis J. (1999). HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. Journal of Virology. 73:2994-3003.
77. Hofmann W, Schubert D, LaBonte J, Munson L, Gibson S, Scammell J, Ferrigno P and Sodroski J. (1999). Species-specific, postentry barriers to primate immunodeficiency virus infection. Journal of Virology. 73:10020-10028.
78. Huang M, Orenstein JM, Martin MA and Freed EO. (1995). p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. Journal of Virology. 69:6810-6818.
79. Kalpana GV, Marmon S, Wang W, Crabtree GR and Goff SP. (1994). Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 266:2002-2006.
80. Kamine J and Chinnadurai G. (1992). Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1. Journal of Virology. 66:3932-3936.
81. Kamine J, Subramanian T and Chinnadurai G. (1991). Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein. Proceedings of the National Academy of Sciences USA. 88:8510-8514.
82. Kaplan AH. (2002). Assembly of the HIV-1 core particle. AIDS Reviews. 4:104-111.
83. Karageorgos L, Li P and Burrell C. (1993). Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Research and Human Retroviruses. 9:817-823.
84. Keckesova Z, Ylinen LM and Towers GJ. (2004). The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proceedings of the National Academy of Sciences USA. 101:10780-10785.
85. Kingsman SM and Kingsman AJ. (1996). The regulation of human immunodeficiency virus type-1 gene expression. European Journal of Biochemistry. 240:491-507.
86. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC and Montagnier L. (1984). T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 312:767-768.
87. Kootstra NA, Munk C, Tonnu N, Landau NR and Verma IM. (2003). Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proceedings of the National Academy of Sciences USA. 100: 1298-1303.
88. Kozak CA and Chakraborti A. (1996). Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology. 225:300-305.
89. Lecossier D, Bouchonnet F, Clavel F and Hance AJ. (2003). Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300:1112.
90. Lee MS and Craigie R. (1994). Protection of retroviral DNA from autointegration: involvement of a cellular factor. Proceedings of the National Academy of Sciences USA. 91:9823-9827.
91. Lee MS and Craigie R. (1998). A previously unidentified host protein protects retroviral DNA from autointegration. Proceedings of the National Academy of Sciences USA. 95:1528-1533.
92. Lewis PF and Emerman M. (1994). Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. Journal of Virology. 68:510-516.
93. Li CJ, Wang C, Friedman DJ and Pardee AB. (1995). Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proceeding of the National Academy of Sciences USA. 92:5461-5464.
94. Li L, Farnet CM, Anderson WF and Bushman FD. (1998). Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro. Journal of Virology. 72:2125-2131.
95. Li L, Yoder K, Hansen MS, Olvera J, Miller MD and Bushman FD. (2000). Retroviral cDNA integration: stimulation by HMG I family proteins. Journal of Virology. 74:10965-10974.
96. Liao Z, Graham DR and Hildreth JE. (2003). Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible, cells. AIDS Research and Human Retroviruses. 19:675-687.
97. Liao Z, Cimakasky LM, Hampton R, Nguyen DH and Hildreth JE. (2001). Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Research and Human Retroviruses. 17:1009-1019.
98. Lilly F. (1967). Susceptibility to two strains of Friend leukemia virus in mice. Science. 155:461-462.
99. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA and Landau NR. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:367-377.
100. Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M and Poeschla EM. (2004). LEDGF/p75 Determines Cellular Trafficking of Diverse Lentiviral but Not Murine Oncoretroviral Integrase Proteins and Is a Component of Functional Lentiviral Preintegration Complexes. Journal of Virology. 78:9524-9537.
101. Luban J, Bossolt KL, Franke EK, Kalpana GV and Goff SP. (1993). Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 73:1067-1078.
102. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L and Trono D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 424:99-103.
103. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H and Landau NR. (2003). Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114:21-31.
104. Martin-Serrano J, Zang T and Bieniasz PD. (2001). HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nature Medicine. 7:1313-1319.
105. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D and Hope TJ. (2003). Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science. 300:1295-1297.
106. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M and Hope TJ. (2002). Visualization of the intracellular behavior of HIV in living cells. Journal of Cell Biology. 159:441-452.
107. Miller MD, Farnet CM and Bushman FD. (1997). Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. Journal of Virology. 71:5382-5390.
108. Moore JP and Stevenson M. (2000). New targets for inhibitors of HIV-1 replication. Nature Reviews Molecular Cell Biology. 1:40-49.
109. Mouzaki A, Doucet A, Mavroidis E, Muster L and Rungger D. (2000). A repression-derepression mechanism regulating the transcription of human immunodeficiency virus type 1 in primary T cells. Molecular Medicine. 6:377-390.
110. Munk C, Brandt SM, Lucero G and Landau NR. (2002). A dominant block to HIV-1 replication at reverse transcription in simian cells. Proceedings of the National Academy of Sciences USA. 99:13843-13848.
111. Nakamura M, Singh DP, Kubo E, Chylack LT, Jr. and Shinohara T. (2000). LEDGF: survival of embryonic chick retinal photoreceptor cells. Investigations in Ophthalmology and Vis Sciences. 41:1168-1175.
112. Nermut MV and Fassati A. (2003). Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. Journal of Virology. 77:8196-8206.
113. Nguyen DH and Taub D. (2002). CXCR4 function requires membrane cholesterol: implications for HIV infection. Journal of Immunology. 168:4121-4126.
114. Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I and Pomerantz RJ. (2002). Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS. 16:39-45.
115. Ott DE. (2002). Potential roles of cellular proteins in HIV-1. Reviews in Medical Virology. 12:359-374.
116. Owens CM, Yang PC, Gottlinger H and Sodroski J. (2003). Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. Journal of Virology. 77:726-731.
117. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M and Sodroski J. (2004). Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. Journal of Virology. 78:5423-5437.
118. Pereira LA, Bentley K, Peeters A, Churchill MJ and Deacon NJ. (2000). A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Research. 28:663-668.
119. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC and Sodroski J. (2004). TRIM5 (alpha) mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proceedings of the National Academy of Sciences USA. 101: 11827-11832.
120. Peterson CL. (1998). SWI/SNF complex: dissection of a chromatin remodeling cycle. Cold Spring Harbor Symposium of Quantitative Biology. 63:545-552.
121. Peterson CL and Tamkun JW. (1995). The SWI-SNF complex: a chromatin remodeling machine? Trends in Biochemical Sciences. 20:143-146.
122. Pincus T, Hartley JW and Rowe WP. (1971). A major genetic locus affecting resistance to infection with murine leukemia viruses. I. Tissue culture studies of naturally occurring viruses. Journal of Experimental Medicine. 133:1219-1233.
123. Pomerantz RJ. (1999). HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy. American Family Physician. 59:2855.
124. Pomerantz RJ. (1999). Residual HIV-1 disease in the era of highly active antiretroviral therapy. New England Journal of Medicine. 340:1672-1674.
125. Pomerantz RJ. (2001). Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. Aids. 15:1201-1211.
126. Pomerantz RJ. (2001). Initiating antiretroviral therapy during HIV infection: confusion and clarity. Journal of American Medical Association. 286:2597-2599.
127. Popik W and Pitha PM. (2000). Exploitation of cellular signaling by HIV-1: unwelcome guests with master keys that signal their entry. Virology. 276:1-6.
128. Popik W, Alce TM and Au WC. (2002). Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. Journal of Virology. 76:4709-4722.
129. Popovic M, Sarngadharan MG, Read E and Gallo RC. (1984). Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 224:497-500.
130. Pornillos O, Alam SL, Rich RL, Myszka DG, Davis DR and Sundquist WI. (2002). Structure and functional interactions of the Tsg101 UEV domain. European Molecular Biology Organization Journal. 21:2397-2406.
131. Rabson AB and Lin HC. (2000). NF-kappa B and HIV: linking viral and immune activation. Advances in Pharmacology, 48:161-207.
132. Rasheed S and Gardner MB. (1983). Resistance to fibroblasts and hematopoietic cells to ecotropic murine leukemia virus infection; an Akvr-IR gene effect. International Journal of Cancer. 31:491-496.
133. Raulin J. (2002). Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Progress in Lipid Research. 41:27-65.
134. Rowland-Jones S, Pinheiro S and Kaul R. (2001). New insights into host factors in HIV-1 pathogenesis. Cell. 104:473-476.
135. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G and Parmentier M. (1996). Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:722-725.
136. Saphire AC, Bobardt MD and Gallay PA. (2000). Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells. Immunology Research. 21:211-217.
137. Sayah DM, Sokolskaja E, Berthoux L and Luban J. (2004). Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 430:569-573.
138. Sheehy AM, Gaddis NC and Malim MH. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV- 1 Vif. Nature Medicine. 9:1404-1407.
139. Sheehy AM, Gaddis NC, Choi JD and Malim MH. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:646-650.
140. Sherman MP and Greene WC. (2002). Slipping through the door: HIV entry into the nucleus. Microbes and Infection. 4:67-73.
141. Simon JH, Gaddis NC, Fouchier RA and Malim MH. (1998). Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature Medicine. 4:1397-1400.
142. Singh DP, Fatma N, Kimura A, Chylack LT, Jr. and Shinohara T. (2001). LEDGF binds to heat shock and stress-related element to activate the expression of gress-related genes. Biochemical and Biophysical Research Communications. 283:943-955.
143. Stevenson V. (2003). HIV-1 pathogenesis. Nature Medicine. 9:853-860.
144. Stopak K, de Noronha C, Yonemoto W and Greene WC. (2003). HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell. 12:591-601.
145. Stoye JP. (1998). Fv1, the mouse retrovirus resistance gene. Reviews in Science and Technology. 17:269-277.
146. Stoye JP. (2001). Endogenous retroviruses: still active after all these years? Current Biology. 11:R914-916.
147. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P and Sodroski J. (2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 427:848-853.
148. Sverdlov ED. (2000). Retroviruses and primate evolution. Bioessays. 22:161-171.
149. Tang H, Peng T and Wong-Staal F. (2002). Novel technologies for studying virus-host interaction and discovering new drug targets for HCV and HIV. Current Opinions in Pharmacology. 2:541-547.
150. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR and Litvak S. (2002). Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Current Pharmacology Design. 8:595-614.
151. Thali M. (1995). Cyclosporins: immunosuppressive drugs with anti-HIV-1 activity. Molecular Medicine Today. 1:287-291.
152. Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J and Gottlinger HG. (1994). Functional association of cyclophilin A with HIV-1 virions. Nature. 372:363-365.
153. Towers G, Collins M and Takeuchi Y. (2002). Abrogation of Ref1 retrovirus restriction in human cells. Journal of Virology. 76:2548-2550.
154. Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP and Danos O. (2000). A conserved mechanism of retrovirus restriction in mammals. Proceedings of the National Academy of Sciences USA. 97:12295-12299.
155. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J and Bieniasz PD. (2003). Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Medicine. 9:1138-1143.
156. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J and Carter CA. (2001). Tsgl0l, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proceedings of the National Academy of Sciences USA. 98:7724-7729.
157. Viard M, Parolini I, Sargiacomo M, Fecchi K, Ramoni C, Ablan S, Ruscetti FW, Wang JM and Blumenthal R. (2002). Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. Journal of Virology. 76:11584-11595.
158. Vilmer E, Barre-Sinoussi F, Rouzioux C, Gazengel C, Brun FV, Dauguet C, Fischer A, Manigne P, Chermarm JC, Griscelli C and et al. (1984). Isolation of new lymphotropic retrovirus from two siblings with haemophilia B, one with AIDS. Lancet. 1:753-757.
159. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL and Crabtree GR. (1996). Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. European Molecular Biology Organization Journal. 15:5370-5382.
160. Wei P, Garber ME, Fang SM, Fischer WH and Jones KA. (1998). A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:451-462.
161. Weiss RA, Griffiths D, Takeuchi Y, Patience C and Venables PJ. (1999). Retroviruses: ancient and modern. Archives in Virology Supplement. 15:171-177.
162. Wiederrecht G, Lam E, Hung S, Martin M and Sigal N. (1993). The mechanism of action of-FK-506 and cyclosporin A. Annals of New York Academy of Sciences. 696:9-19.
163. Wolffe AP. (2001). Transcriptional regulation in the context of chromatin structure. Essays in Biochemistry. 37:45-57.
164. Yap MW, Nisole S, Lynch C and Stoye JP. (2004). Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proceedings of the National Academy of Sciences USA. 101:10786-10791.
165. Yedavalli VS, Benkirane M and Jeang KT. (2003). Tat and transactivation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin Tl requires Spl. Journal of Biological Chemistry. 278:6404-6410.
166. Yung E, Sorin M, Wang EJ, Perumal S, Ott D and Kalpana GV. (2004). Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance. Journal of Virology. 78:2222-2231.
167. Yung E, Sorin M, Pal A, Craig E, Morozov A, Delattre O, Kappes J, Ott D and Kalpana GV. (2001). Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nature Medicine. 7:920-926.
168. Zhang H, Dornadula G and Pomerantz RJ. (1996). Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells. Journal of Virology. 70:2809-2824.
169. Zhang H, Dornadula G and Pomerantz RJ. (1998). Natural endogenous reverse transcription of HIV type 1. AIDS Research and Human Retroviruses. 14 Supplement 1:S93-95.
170. Zhang H, Dornadula G, Orenstein J and Pomerantz RJ. (2000). Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact vital core. Journal of Human Virology. 3:165-172.
171. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC and Gao L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424:94-98.
172. Zimmerman C, Klein KC, Kiser PK, Singh AR, Firestein BL, Riba SC and Lingappa JR. (2002). Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature. 415:88-92.